Active Biotech Q2’22: Our comments - Redeye
Bildkälla: Stockfoto

Active Biotech Q2’22: Our comments - Redeye

Redeye comments on Active Biotech's second quarter report and the rights issue that was simultaneously announced.

Börsvärldens nyhetsbrev